What is N-terminal pro B-type natriuretic peptide (NT-proBNP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is NT-proBNP?

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is an inactive breakdown product released from cardiac myocytes in response to mechanical stretch from volume or pressure overload, serving as a semi-quantitative biomarker for cardiac stress and heart failure diagnosis, prognosis, and treatment monitoring. 1

Biochemistry and Production

NT-proBNP is formed when the heart produces BNP (B-type natriuretic peptide) in response to cardiac stress. The process begins with a pre-prohormone that is split to form proBNP, which is then further broken down into two components: the biologically active hormone BNP 1-32 and the inactive breakdown product NT-proBNP. 1

The primary stimulus for production is myocyte stretch mediated by both pressure and volume overload, with hypoxia also identified as a contributing factor. 1 Production occurs more rapidly and extensively in the ventricles than in the atria, particularly during periods of cardiac strain. 1

Half-Life and Clearance

NT-proBNP has a significantly longer biological half-life compared to BNP:

  • NT-proBNP half-life: 25 to 70 minutes 1
  • BNP half-life: 13 to 20 minutes 1

This longer half-life explains why NT-proBNP values are consistently higher than BNP values and makes NT-proBNP more stable for laboratory testing. 1

NT-proBNP is cleared passively by organs with high blood flow, with the following distribution of total body clearance: 1

  • 55-65% by the kidneys
  • 20-25% across the liver
  • 10-15% across musculoskeletal tissue
  • 5-10% across the head and neck

Both BNP and NT-proBNP are extracted renally by 15-20% in healthy individuals, and both increase with renal failure. 1 However, in severe renal dysfunction (GFR <30 mL/min/1.73 m²), NT-proBNP/BNP ratios increase disproportionately. 1

Normal Reference Ranges

NT-proBNP levels vary by age and sex: 1, 2

  • Young adults: <70 pg/mL
  • Ages 45-59 years: <164 pg/mL (females)
  • Ages >60 years: <225 pg/mL (females)

Males consistently have lower levels than females, likely due to androgen suppression of pro-BNP synthesis. 1 Higher body mass index results in lower normal values, though the mechanism remains unclear. 1

Clinical Significance

NT-proBNP is neither heart failure nor heart disease specific - it is a semi-quantitative marker of cardiac stress related to the extent of atrial, ventricular, and valvular dysfunction. 1

Conditions that elevate NT-proBNP include: 1

  • Acute or chronic systolic or diastolic heart failure (left and right)
  • Valvular heart disease
  • Left ventricular hypertrophy with or without hypertension
  • Atrial fibrillation
  • Pulmonary embolism and severe pulmonary hypertension
  • Acute or chronic renal failure
  • Advanced liver cirrhosis with ascites
  • Anemia and sepsis
  • Endocrine disorders (hyperaldosteronism, Cushing's syndrome, hyperthyroidism)
  • Severe neurological disease (subarachnoid hemorrhage, stroke, trauma)

Diagnostic Applications

NT-proBNP is primarily used for diagnosis, management, and prognostication of cardiac failure. 1 The biomarker has high sensitivity for ruling out heart failure at lower thresholds and strong positive predictive value at higher thresholds. 3

Age-adjusted diagnostic cut-offs for acute heart failure: 2

  • **<50 years**: >450 pg/mL
  • 50-75 years: >900 pg/mL
  • >75 years: >1,800 pg/mL

For exclusion of heart failure, NT-proBNP <300 pg/mL has a 98% negative predictive value. 3, 2

Prognostic Value

NT-proBNP should be interpreted as a continuous variable, with higher values indicating greater risk regardless of the underlying cause. 1, 3 For each 500 pg/mL increase in NT-proBNP above baseline in patients with mild to moderate cardiac failure, there is an associated 3.8% increased mortality risk. 2

Sample Stability

NT-proBNP is more stable than BNP for laboratory testing. 1 The biomarker is stable at room temperature for at least 2 days, with long-term stability of at least 4 months at -20°C and at least 1 year at -80°C. 1

Important Caveats

Obesity can lead to lower NT-proBNP levels, potentially masking cardiac dysfunction. 3, 2 Renal dysfunction elevates values, particularly for NT-proBNP compared to BNP. 2 Acute conditions like sepsis and atrial fibrillation can affect accuracy and interpretation. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pro-BNP Level: A Diagnostic Biomarker for Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

BNP Levels and Heart Failure Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.